Inventor
Peter Kufer
Inventor
Munich, DE
Overview
Patents· 44 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides30%
A61KPreparations for medical, dental or toiletry purposes28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
C12NMicroorganisms or enzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
A01KAnimal husbandry1%
C40BCombinatorial chemistry1%
PatentTitleYear
11,084,876Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains202111,079,381Risk-stratification of B-precursor acute lymphoblastic leukemia patients202111,053,318Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia202111,028,171Bispecific antibody constructs for CDH3 and CD3202110,981,998Cross-species-specific single domain bispecific single chain antibody202110,781,264PSMA and CD3 bispecific T cell engaging antibody constructs202010,766,969Binding molecules for BCMA and CD3202010,752,694Binding molecules for BCMA and CD3202010,683,351Antibody constructs for DLL3 and CD3202010,662,243Dosage regimen for administering a CD19XCD3 bispecific antibody202010,519,241Antibody constructs for EGFRVIII and CD3201910,301,391BCMA and CD3 bispecific T cell engaging antibody constructs201910,294,300Antibody constructs for DLL3 and CD3201910,059,766Antibody constructs for CDH19 and CD3201810,047,159Bispecific single chain antibodies with specificity for high molecular weight target antigens20189,982,063Pharmaceutical compositions with resistance to soluble CEA20189,765,157'Antibody constructs for CDH19 and CD3'20179,695,250'Pharmaceutical compositions with resistance to soluble CEA'20179,688,760'Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains'20179,598,500'Binding molecules for BCMA and CD3'20179,587,036'Cross-species-specific PSMAxCD3 bispecific single chain antibody'20179,505,849'Antibody constructs for influenza M2 and CD3'20169,486,475'PPS for the prevention of potential adverse effects caused by CD3 specific binding domains'20169,340,621'Binding molecules for BCMA and CD3'20169,260,522'Bispecific single chain antibodies with specificity for high molecular weight target antigens'20169,150,664'Binding molecules for BCMA and CD3'20158,901,278'Pharmaceutical antibody compositions with resistance to soluble CEA'20148,840,888'Dosage regimen for administering a CD19XCD3 bispecific antibody'20148,790,645'Pharmaceutical composition comprising a bispecific antibody for EpCAM'20148,784,821'Human-anti-human cd3 binding molecules'20148,394,926'Pharmaceutical compositions with resistance to soluble CEA'20138,236,308'Composition comprising cross-species-specific antibodies and uses thereof'20128,101,722'Less immunogenic binding molecules'20128,007,796'Means and methods for the treatment of tumorous diseases'20117,919,089'Pharmaceutical composition comprising a bispecific antibody for EpCAM'20117,635,472'Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders'20097,632,925'Antibodies that bind human 17-A1/EpCAM tumor antigen'20097,575,923'CD19xCD3 specific polypeptides and uses thereof'20097,491,814'Real-time RT-PCR for the sensitive detection of multiple MAGE gene transcripts'20097,435,549'Method of identifying binding site domains that retain the capacity of binding to an epitope'20087,235,641'Bispecific antibodies'20077,227,002'Human antibodies that bind human 17-A1/EpCAM tumor antigen'20077,112,324'CD 19×CD3 specific polypeptides and uses thereof'20066,475,727'Primers and methods for the detection of disseminated tumor cells'2002Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2002–2014Patents assigned to MICROMET AG (14)· patent assignee history
2002–2017Based in Moosburg, DE· patent location history
2007–2021Based in Munich, DE· patent location history
2009–2021Patents assigned to KUFER PETER (11)· patent assignee history
2012–2021Patents assigned to RAUM TOBIAS (7)· patent assignee history
2014–2021Patents assigned to AMGEN RES MUNICH GMBH (29)· patent assignee history
2017–2021Patents assigned to AMGEN INC (7)· patent assignee history
2017Based in Münich, DE· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| AMGEN RES MUNICH GMBH | 29 | 2014–2021 |
| MICROMET AG | 14 | 2002–2014 |
| KUFER PETERself | 11 | 2009–2021 |
| AMGEN INC | 7 | 2017–2021 |
| RAUM TOBIAS | 7 | 2012–2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| Munich, DE | 26 | 2007–2021 |
| Moosburg, DE | 17 | 2002–2017 |
| Münich, DE | 1 | 2017 |